Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...

Minimally invasive surgery in genitourinary oncology has undergone significant transformation in recent years due to the integration of advanced ...

Clinical trial participation is associated with improved survival for patients with some genitourinary cancers, but racial, ethnic, age, gender, and socioeconomic disparities appe ...

The evolution of genitourinary cancer treatment includes a shift from monotherapies to combination therapies, improving survival and quality of life. Combining androgen blockers with DNA repair ...

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications. The Hugo™ robotic-assisted surgery (RAS) system is safe and effective, ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...

Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...

Designing and Validating a Comprehensive Patient-Reported Outcomes Measure for Ambulatory Cancer Settings: The Revised Edmonton Symptom Assessment System for Cancer We retrospectively analyzed ...